Neumora Therapeutics Q3 2026 Earnings Date & Estimates

Neumora Therapeutics (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. The company combines neuroscience, data science and machine-learning technologies to identify disease mechanisms, discover potential therapies and develop more targeted medicines for patients with neurological and neuropsychiatric disorders.

Neumora’s pipeline has included navacaprant, also known as NMRA-140, an investigational selective kappa opioid receptor antagonist being studied for major depressive disorder and related symptoms such as anhedonia, or the loss of interest and pleasure. The company has also pursued additional programs for disorders of the central nervous system, supported by its data-driven NeuroDiscovery platform.

Neumora was founded in 2019 and is headquartered in Watertown, Massachusetts. The company became a publicly traded business on the Nasdaq under the symbol NMRA in 2023. Its operations and clinical development activities are primarily centered in the United States, with clinical research conducted through relevant international study sites as applicable. Henry Gosebruch serves as chief executive officer.